F Andre

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
  2. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
  3. ncbi request reprint Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
    F Andre
    Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:vi46-51. 2012
  4. doi request reprint Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
    F Andre
    Department of Medical Oncology, Institute Gustave Roussy, Villejuif, France
    Ann Oncol 23:2059-64. 2012
  5. doi request reprint Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups
    Fabrice Andre
    Department of Medical Oncology, Institut National de la Sante et de la Recherche Medicale, France
    Clin Cancer Res 18:1555-60. 2012
  6. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
  7. pmc Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010
  8. doi request reprint Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    Fabrice Andre
    Translational Research Unit, UPRES03535, Paris Sud University, Orsay, France
    Clin Cancer Res 15:441-51. 2009
  9. ncbi request reprint Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
    F Andre
    Department of Medicine and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:945-51. 2006
  10. doi request reprint Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, France
    Curr Opin Oncol 22:547-51. 2010

Detail Information

Publications55

  1. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
    ..This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis...
  2. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
    ..We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer...
  3. ncbi request reprint Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
    F Andre
    Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:vi46-51. 2012
    ..Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs...
  4. doi request reprint Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer
    F Andre
    Department of Medical Oncology, Institute Gustave Roussy, Villejuif, France
    Ann Oncol 23:2059-64. 2012
    ..The purpose of this study was to evaluate the prognostic and predictive value of p27 expression in patients with early breast cancer...
  5. doi request reprint Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups
    Fabrice Andre
    Department of Medical Oncology, Institut National de la Sante et de la Recherche Medicale, France
    Clin Cancer Res 18:1555-60. 2012
    ..The programs are being run by cooperative groups...
  6. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  7. pmc Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 15:476-83. 2010
    ..In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression...
  8. doi request reprint Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    Fabrice Andre
    Translational Research Unit, UPRES03535, Paris Sud University, Orsay, France
    Clin Cancer Res 15:441-51. 2009
    ..We used high-resolution oligonucleotide comparative genomic hybridization (CGH) arrays and matching gene expression array data to identify dysregulated genes and to classify breast cancers according to gene copy number anomalies...
  9. ncbi request reprint Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer
    F Andre
    Department of Medicine and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 17:945-51. 2006
    ..In the present study, we evaluated the association between the chemokine receptors expressed in primary tumor cells and the site of metastatic relapse in patients with breast cancer...
  10. doi request reprint Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, France
    Curr Opin Oncol 22:547-51. 2010
    ..This review will summarize recent advances concerning the implication of tumor microenvironment in the response to chemotherapy...
  11. ncbi request reprint Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer
    Fabrice Andre
    Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, Villejuif, France
    J Clin Oncol 23:2996-3000. 2005
    ..We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines...
  12. doi request reprint Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, University Paris XI and Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 28:5110-5. 2010
    ....
  13. doi request reprint Biomarker studies: a call for a comprehensive biomarker study registry
    Fabrice Andre
    Department of Medical Oncology and INSERM U981 Institut Gustave Roussy, 39 rue Camilles Desmoulins, Villejuif 94805, France
    Nat Rev Clin Oncol 8:171-6. 2011
    ..The benefits of a comprehensive biomarker study registry include more balanced evaluation of proposed markers, fewer false positive leads in research, and hopefully more rapid identification of promising candidate biomarkers...
  14. ncbi request reprint Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications
    F Andre
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 18:2981-9. 2000
    ..We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups...
  15. doi request reprint [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]
    Y Bensouda
    Departement de Medecine, Comité de Pathologie Mammaire, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 96:923-8. 2009
    ..003). these data confirm that CA 15-3 is very variably elevated at time of metastatic relapse of breast cancer, and this is dependant on HR status...
  16. ncbi request reprint Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
    F Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:315-20. 2008
    ..We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues...
  17. ncbi request reprint Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
    R Conforti
    Translational Research Unit, Unité Propre de Recherche de l Enseignement Supérieur, équipe d accueil 03535, Villejuif, France
    Ann Oncol 18:1477-83. 2007
    ..The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy...
  18. ncbi request reprint Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  19. doi request reprint p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
    F C Bidard
    Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1261-5. 2008
    ..We analysed the efficacy of a preoperative combination between 5-fluorouracil, anthracyclines and cyclophosphamide according to both p53 status and molecular classification...
  20. doi request reprint ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
    B Besse
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:575-81. 2011
    ..We hypothesised that there might be an increased incidence of BMs in ERCC1-negative non-SCCs when treated with adjuvant cisplatin-based chemotherapy...
  21. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  22. doi request reprint Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy
    M C Mathieu
    Breast Cancer Unit, Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:2046-52. 2012
    ..Breast Cancer Index (BCI) predicts recurrence risk in estrogen receptor+lymph node-breast cancer. Performance of BCI to predict chemosensitivity based on pathological complete response (pCR) and BCS was assessed...
  23. ncbi request reprint What can breast cancer molecular sub-classification add to conventional diagnostic tools?
    F Andre
    Breast Cancer Unit and Translational Research Unit, Institut Gustave Roussy, Villejuif
    Ann Oncol 18:ix33-6. 2007
  24. ncbi request reprint Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?
    F Andre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Cancer 91:2394-400. 2001
    ..The purpose of the current study was to analyze the patterns of relapse in these patients...
  25. pmc Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
    ..Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined...
  26. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  27. doi request reprint Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
    M Zoubir
    Translational Research Unit, UPRES EA035, Universite Paris XI, Institut Gustave Roussy, Villejuif
    Ann Oncol 19:1402-6. 2008
    ..Phosphorylation of serine 118 (ser118) has been reported to be involved in the activation of estrogen receptor (ER). In the present study, we evaluated whether endocrine therapy modulated ER phosphorylation on ser118...
  28. ncbi request reprint DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Biochim Biophys Acta 1766:197-204. 2006
    ..Next, we will compare advantages and limitations of cohort-based and case-control studies. The choice of end-point to discriminate between sensitive and resistant patients will also be examined...
  29. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  30. ncbi request reprint Risk factors for brain relapse in patients with metastatic breast cancer
    K Slimane
    Breast Cancer Unit, Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:1640-4. 2004
    ..The occurrence of brain metastases is an emerging problem in patients with metastatic breast cancer. In the present study, we looked at risk factors for brain metastasis among patients with metastatic breast cancer...
  31. doi request reprint Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
    N Berrada
    Department of Medical Oncology and INSERM Unit U981, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii30-5. 2010
    ..Several other targeted agents are being developed in this setting, including epidermal growth factor receptor (EGFR), FGFR2, mammalian target of rapamycin (mTOR) and NOTCH inhibitors...
  32. pmc Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening
    E Ruiz-Garcia
    Breast Cancer Translational Research Unit, UPRES EA03535, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 102:462-8. 2010
    ..There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening...
  33. doi request reprint Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
    M Arnedos
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:2293-9. 2012
    ....
  34. pmc A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes
    B Dutta
    Department of Systems Biology Unit 950, The University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA
    Br J Cancer 106:1107-16. 2012
    ..For example, diverse transcriptomic and gene copy number variation data are currently collected for various cancers, but relatively few current methods are capable to utilise the emerging information...
  35. ncbi request reprint Tumor-derived exosomes: a new source of tumor rejection antigens
    F Andre
    Unite d immunologie, Immunology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, F 94805 Villejuif Cedex, France
    Vaccine 20:A28-31. 2002
    ..Here, we will describe the biochemical properties of tumor-derived exosomes and, their pre-clinical activity as cancer vaccines...
  36. ncbi request reprint A study of the immunological response to tumor ablation with irreversible electroporation
    B Al-Sakere
    UMR 8121 CNRS Institut, Gustave Roussy, 39 Rue C Desmoulins, F 94805 Villejuif, France
    Technol Cancer Res Treat 6:301-6. 2007
    ..We confirm here that immune response is not instrumental in irreversible electroporation efficacy, and we propose that irreversible electroporation may be, therefore, a treatment modality of interest to immunodepressed cancer patients...
  37. doi request reprint CXCR4 expression in early breast cancer and risk of distant recurrence
    Fabrice Andre
    Breast Medical Oncology Unit, Department of Radiation Therapy, Department of Pathology and Translational Research Unit UPRES EA03535, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Oncologist 14:1182-8. 2009
    ..e., liver, lung, brain, and bone)...
  38. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  39. doi request reprint Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer
    Catherine Uzan
    Research Translational Laboratory, Histocytopathology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, Villejuif, France
    Cancer 117:32-9. 2009
    ..The objective of the current study was to evaluate the quality and potential use of material obtained from fine-needle aspiration cytology (FNAC)...
  40. pmc Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
    C Mazouni
    Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
    Br J Cancer 99:68-71. 2008
    ..In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy...
  41. pmc A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
    F Farace
    Translational Research Laboratory, Institut de Cancerologie Gustave Roussy, 94805 Villejuif, France
    Br J Cancer 105:847-53. 2011
    ..However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay)...
  42. ncbi request reprint Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    Fabrice Andre
    Breast Cancer Unit and Translational Research Unit, UPRES03535, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:2061-7. 2007
    ..A molecular marker may be prognostic of outcome or predictive of response to therapy, or a combination of both...
  43. doi request reprint Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  44. doi request reprint Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
    S Guiu
    Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France
    Ann Oncol 23:2997-3006. 2012
    ..Methods for breast cancer classification into molecular subtypes should, however, be incorporated into clinical trial design...
  45. ncbi request reprint A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
    E Massarelli
    MD Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, P O Box 432, Houston, TX 77030, USA
    Lung Cancer 39:55-61. 2003
    ..02). This review highlights the need for novel therapy approaches for patients with recurrent NSCLC who have failed second-line therapy and provides a baseline for the statistical design of such studies...
  46. ncbi request reprint Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  47. doi request reprint Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  48. ncbi request reprint Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Nat Clin Pract Oncol 3:621-32. 2006
    ..This Review describes the current limitations and future promises of gene-expression-based molecular classification of breast cancer and how it might impact on selection of adjuvant therapy for individual patients...
  49. ncbi request reprint Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy
    Fabrice Andre
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Pharm Res 23:1951-8. 2006
    ....
  50. ncbi request reprint Exosomes for cancer immunotherapy
    F Andre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:iv141-4. 2004
  51. ncbi request reprint Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast
    Julien Grenier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif
    Anticancer Res 27:547-55. 2007
    ..Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour. An attempt was made to characterize its differential immunohistochemical and biological profile...
  52. ncbi request reprint Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  53. ncbi request reprint Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  54. ncbi request reprint Malignant effusions and immunogenic tumour-derived exosomes
    Fabrice Andre
    Departments of Clinical Biology, Immunology Unit, Institut Gustave Roussy, Villejuif, France
    Lancet 360:295-305. 2002
    ..To assess the role of these exosomes in vivo, we examined malignant effusions for their presence. We also investigated whether these exosomes could induce production of tumour-specific T cells when pulsed with dendritic cells...
  55. pmc Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
    ..Multigenic predictors were designed by selecting probe sets highly ranked in their predictions and tested using several validation sets...